Merck Posts Strong Q4 Sales, Beats Estimates, but Cautious Outlook Weighs on Investor Sentiment
Pharmaceutical giant Merck & Co. reported fourth-quarter revenue that surpassed Wall Street forecasts, driven by robust demand for its key products. However, a more conservative full-year sales projection and a sharp expected decline in earnings for the coming year tempered the positive results, sending shares lower in after-hours trading.